Edition:
United States

ContraVir Pharmaceuticals Inc (CTRV.OQ)

CTRV.OQ on NASDAQ Stock Exchange Capital Market

0.34USD
15 Dec 2017
Change (% chg)

$-0.01 (-1.48%)
Prev Close
$0.35
Open
$0.35
Day's High
$0.36
Day's Low
$0.34
Volume
96,976
Avg. Vol
193,252
52-wk High
$1.99
52-wk Low
$0.32

Latest Key Developments (Source: Significant Developments)

Contravir Pharmaceuticals receives HBV IND approval for tenofovir exalidex in the U.S.
Monday, 11 Sep 2017 06:00am EDT 

Sept 11 (Reuters) - Contravir Pharmaceuticals Inc ::Contravir Pharmaceuticals receives hbv ind approval for tenofovir exalidex (txl™) in the United States.Contravir Pharmaceuticals - ‍intends to initiate U.S.-based clinical trial for txl in q4 of 2017, pending approval by institutional review board​.Contravir Pharmaceuticals - ‍ intends to initiate its first us-based clinical trial for txl in Q4 2017, pending approval by institutional review board​.  Full Article

U.K. accepts Contravir Pharma's clinical trial application
Wednesday, 6 Sep 2017 06:00am EDT 

Sept 6 (Reuters) - Contravir Pharmaceuticals Inc :Contravir Pharmaceuticals announces acceptance of clinical trial application in the United Kingdom.Contravir Pharmaceuticals Inc - ‍contravir expects to dose its first patient in uk before end of this month​.Contravir Pharmaceuticals Inc - ‍contravir expects to dose its first patient in uk before end of this month​.  Full Article

ContraVir Pharma to advance second-gen formulation of Tenofovir Exalidex
Thursday, 4 May 2017 06:00am EDT 

May 4 (Reuters) - Contravir Pharmaceuticals Inc :Contravir pharmaceuticals - contravir to advance second-generation formulation of tenofovir exalidex for treatment of hepatitis b virus (hbv).  Full Article

Contravir Pharmaceuticals says offering of 12 mln common shares priced at $1/ share
Tuesday, 25 Apr 2017 09:00am EDT 

April 25 (Reuters) - Contravir Pharmaceuticals Inc ::Contravir Pharmaceuticals announces pricing of public offering of common stock and warrants.Says offering of 12.0 million common shares priced at $1.00per share.Says intends to use net proceeds from sale of securities to fund research and development activities.  Full Article

Contravir Pharmaceuticals announces proposed public offering of common stock
Monday, 24 Apr 2017 04:01pm EDT 

April 24 (Reuters) - Contravir Pharmaceuticals Inc : :Contravir Pharmaceuticals announces proposed public offering of common stock and warrants.Contravir Pharmaceuticals Inc - intends to use net proceeds from sale of securities to fund research and development activities.  Full Article

Contravir expands scientific advisory board for Hepatitis B
Monday, 18 Jul 2016 06:00am EDT 

Contravir Pharmaceuticals : Carol L. Brosgart appointed chair of SAB in support of Contravir's development of a potentially curative therapy for hbv .Contravir expands scientific advisory board to focus on seeking curative therapy for Hepatitis B.  Full Article

Contravir says doses first patients in head-to-head study of CMX157 vs Viread
Tuesday, 21 Jun 2016 06:29am EDT 

Contravir : Doses first patients in head-to-head study of Cmx157 versus. Viread® for treating hepatitis b . Study is expected to conclude in q4 of 2016 .Phase 1b study in line with expectations into final 100 mg dosing group.  Full Article

Contravir Pharma initiates mid-stage study of CMX157 for treating hepatitis B
Wednesday, 1 Jun 2016 06:00am EDT 

Contravir Pharmaceuticals Inc : Contravir initiates head-to-head phase 2a clinical study of cmx157 versus. viread® for treating hepatitis b .Contravir pharmaceuticals inc says final results from this study are expected in q4 of 2016.  Full Article

Contravir to expand hepatitis B portfolio
Tuesday, 31 May 2016 06:00am EDT 

Contravir Pharmaceuticals Inc : Contravir to expand hepatitis B portfolio through strategic merger agreement with ciclofilin pharmaceuticals . Milestone payments will consist of up to an aggregate $17 million cash and up to 10% of Contravir's issued and outstanding common stock . Merger has been approved by board of directors of both companies . Following completion of transaction, ciclofilin will become a wholly owned subsidiary of contravir. . Contravir to expand hepatitis b portfolio through strategic merger agreement with ciclofilin pharmaceuticals .To quire outstanding equity interests in ciclofilin to receive future milestone payments to be allocated among holders of ciclofilin stock.  Full Article

ContraVir Pharmaceuticals Inc announces proposed public offering of common stock
Tuesday, 29 Mar 2016 04:42pm EDT 

ContraVir Pharmaceuticals Inc:Intends to offer shares of its common stock and warrants to purchase shares of its common stock in a "best efforts" underwritten public offering.  Full Article

BRIEF-Contravir Pharmaceuticals adjourns annual meeting of stockholders until Dec 21

* CONTRAVIR PHARMACEUTICALS ANNOUNCES ADJOURNMENT OF ANNUAL MEETING OF STOCKHOLDERS UNTIL DECEMBER 21, 2017